By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please tack note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Invest directly by choosing one of the brokers below
Get in Touch
Back
HLTH
Tema Healthcare AI ETF
Invest in the AI Transformation of Healthcare
Why Invest in HLTH?
Vast Opportunity
U.S. healthcare spending is forecast to rise from $5.3 trillion in 2024 to $9.0 trillion by 2034, creating a vast opportunity for technologies that reduce waste, improve efficiency, and deliver better care.
Centers of Medicare & Medicaid Services, Jul 2026
Growing AI Adoption
AI adoption in healthcare is among the fastest of any sector, led by its potentially outsized impact on drug discovery and diagnostics, among other medical frontiers.
Stanford, Apr 2026 (growth vs. 2022-2023)
Investment Expertise
HLTH is managed by a Yale- and Penn-trained physician with more than two decades of healthcare investing experience.
Portfolio Highlights
10x Genomics is a life sciences tools company whose single-cell and spatial genomics platforms generate the high-resolution biological data used to train foundational models of human disease.
Intuitive Surgical is the pioneer and global leader in robotic-assisted surgery, whose da Vinci platform combines robotic instrumentation, advanced imaging, data analytics, and AI-enabled software to support surgeons and has been used in more than 20 million procedures worldwide.
Insilico Medicine is an AI-native drug discovery company that uses generative AI and large biological models to identify novel disease targets and design drug candidates at a fraction of the time and cost of traditional methods.
Fund Overview
Fund Details
As of July 31, 2026
Ticker
HLTH
CUSIP
87975E768
Inception Date
07/21/26
Total Expense Ratio
0.75%
Primary Exchange
NASDAQ
# of Holdings
33
Portfolio Manager
David K. Song, MD, PhD, CFA
Fund Summary
The Tema Healthcare AI ETF (HLTH) provides actively managed exposure to companies leveraging AI to transform healthcare across drug discovery, diagnostics, clinical application, and patient care, among other emerging opportunities.
Portfolio Breakdown
Top 10 Holdings
As of July 31, 2026
Company
% of Nav
10X GENOMICS INC
5.38%
ILLUMINA INC
5.13%
CYTOKINETICS INC
4.86%
REVOLUTION MEDICINES INC
4.47%
VERTEX PHARMACEUTICALS INC
4.29%
INTUITIVE SURGICAL INC
4.14%
THERMO FISHER SCIENTIFIC INC
4.12%
COGENT BIOSCIENCES INC
4.10%
DYNE THERAPEUTICS INC
3.97%
ARROWHEAD PHARMACEUTICALS INC
3.94%
Country Breakdown
United States
96.79%Cayman Islands
2.07%Cash & Cash Equivalents
1.15%Industry Breakdown
Health Care
95.67%Financials
3.19%Cash & Cash Equivalents
1.15%- Performance
- Distributions
- Premium / Discount
Prices & Performance
{}
As of
Oct 01, 2024
- Oct 01, 2024
- Oct 01, 2024
HLTH
3 months
1 Year
3 Years
5 Years
Since inception
NAV
Market Price
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.
Distributions
Record Date
Ex-Date
Payable Date
Total Distribution
Income
Premium/Discount
Сhart
Table
Days Traded at Nav
Days Traded at Premium
Days Traded at Discount
HLTH NAV / Market Price
NAV$25.57
Daily Change
-$0.18
-0.69%
Market Price$25.66
Daily Change
-$0.15
-0.60%
Premium/Discount0.32%
30-Day Median Bid/Ask Spread0.39%
As of July 31, 2026
July-26
Portfolio Manager
David K. Song, MD, PhD, CFA
David Song is the Head of Healthcare and Investment Partner at Tema ETFs. David has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton. David is a CFA charter holder.
How to buy
.svg){kind=small}
*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.
Latest Research & Insights
Stay informed with our latest research, insights, and market analysis to make better investment decisions.
CXMT Enters the Global Memory Mainstream
CXMT is quickly becoming a global leader in DRAM, showcasing rapid growth and expanding capacity in the semiconductor market. Explore the opportunity.
How AI Is Poised to Transform Healthcare—And Why It Matters
Explore how AI is transforming healthcare, boosting productivity, and creating investment opportunities through the Tema Healthcare AI ETF.
NAND: The Overlooked Half of the AI Memory Trade
Discover how NAND flash is evolving into a crucial component of AI memory infrastructure, driven by rising demand and constrained supply growth.
Subscribe for Updates
Risk Information
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.
Investing involves risk including possible loss of principal. There is no guarantee the fund's investment strategy will be successful.
Sector Focus Risk: The Fund may invest a significant portion of its assets in one or more sectors and thus will be more susceptible to the risks affecting those sectors than funds that have more diversified holdings across a number of sectors. The Fund anticipates that it may be subject to some or all of the risks described below.
Healthcare Sector Risk: To the extent the Fund focuses on the healthcare sector, the Fund may be more susceptible to the particular risks that may affect companies in the healthcare sector than if it were invested in a wider variety of companies in unrelated sectors. The profitability of companies in the healthcare sector may be adversely affected by the following factors, among others: extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments. The expiration of a company’s patents may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. Many new products in the healthcare sector may be subject to regulatory approvals. The process of obtaining such approvals may be long and costly, and such efforts ultimately may be unsuccessful. Companies in the healthcare sector may be thinly capitalized and may be susceptible to product obsolescence.
Information Technology Sector Risk: Information technology companies face intense competition, both domestically and internationally, which may have an adverse effect on their profit margins. Like other technology companies, information technology companies may have limited product lines, markets, financial resources or personnel. Companies in the information technology sector are heavily dependent on patent and intellectual property rights. The loss or impairment of any of these rights may adversely affect the profitability of these companies or the Fund’s performance.
Tema ETFs LLC serves as the investment adviser to Tema Healthcare AI ETF (the “Fund”), and Tidal Investments LLC serves as a sub-adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.